Comparative Pharmacology
Head-to-head clinical analysis: AFRINOL versus ALLERFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFRINOL versus ALLERFED.
AFRINOL vs ALLERFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
None Documented
None Documented
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Category C
Category C
Decongestant
Decongestant